Document is current
Any future updates will be listed below
-
Authors
Lawn, Will
Hao, Xuejun
Konova, Anna B.
Haney, Margaret
Cooper, Ziva D.
Van Dam, Nicholas
Glimcher, Paul
Bedi, Gillinder https://orcid.org/0000-0002-6718-0099
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (DA034877)
University of Melbourne
- License Information
-
More Information
Article History
Received: 9 July 2024
Accepted: 13 January 2025
First Online: 10 February 2025
Declarations
:
: MH is a stockholder and on the Scientific Advisory Board for Pleo Pharma. Outside of this work, ZDC reports receiving study drug from Canopy Growth Corp. WL provides ad-hoc consultancy for the CRO AxialBridge. GB has acted as an unpaid consultant to atai Life Sciences and Kinoxis Therapeutics. XH, ABK, NVD, and PG, reported no biomedical financial interests or potential conflicts of interest. The research described in this manuscript complies with the laws of the country in which it was performed (USA).
